- Home
- ATLCP vs RVMDW Comparison
ATLCP vs RVMDW Comparison
Compare ATLCP & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLCP
- RVMDW
- Stock Information
- Founded
- ATLCP N/A
- RVMDW N/A
- Country
- ATLCP United States
- RVMDW United States
- Employees
- ATLCP 386
- RVMDW 490
- Industry
- ATLCP Finance: Consumer Services
- RVMDW
- Sector
- ATLCP Finance
- RVMDW
- Exchange
- ATLCP Nasdaq
- RVMDW Nasdaq
- Market Cap
- ATLCP N/A
- RVMDW N/A
- IPO Year
- ATLCP N/A
- RVMDW N/A
- Fundamental
- Price
- ATLCP $23.50
- RVMDW $0.24
- Analyst Decision
- ATLCP
- RVMDW
- Analyst Count
- ATLCP 0
- RVMDW 0
- Target Price
- ATLCP N/A
- RVMDW N/A
- AVG Volume (30 Days)
- ATLCP N/A
- RVMDW N/A
- Earning Date
- ATLCP N/A
- RVMDW N/A
- Dividend Yield
- ATLCP N/A
- RVMDW N/A
- EPS Growth
- ATLCP N/A
- RVMDW N/A
- EPS
- ATLCP N/A
- RVMDW N/A
- Revenue
- ATLCP N/A
- RVMDW N/A
- Revenue This Year
- ATLCP N/A
- RVMDW N/A
- Revenue Next Year
- ATLCP N/A
- RVMDW N/A
- P/E Ratio
- ATLCP N/A
- RVMDW N/A
- Revenue Growth
- ATLCP N/A
- RVMDW N/A
- 52 Week Low
- ATLCP N/A
- RVMDW N/A
- 52 Week High
- ATLCP N/A
- RVMDW N/A
- Technical
- Relative Strength Index (RSI)
- ATLCP 43.18
- RVMDW N/A
- Support Level
- ATLCP $22.72
- RVMDW N/A
- Resistance Level
- ATLCP $23.93
- RVMDW N/A
- Average True Range (ATR)
- ATLCP 0.50
- RVMDW 0.00
- MACD
- ATLCP -0.09
- RVMDW 0.00
- Stochastic Oscillator
- ATLCP 27.22
- RVMDW 0.00
About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About RVMDW Revolution Medicines Inc. Warrant
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.